GIP受体 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-07 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
== Overdose == Overdosage leads to drowsiness, agitation, nausea and anticholinergic effects like tachycardia (high heart rate), dry mouth, blurred vision, glaucoma, or urinary retention. Especially in children, pentoxyverine can cause hypoventilation, but much more seldom than codeine and other opioid antitussives. The treatment of overdosage aims at the symptoms; there are no specific antidotes available.
== Interactions == Enobosarm is a substrate of the cytochrome P450 enzyme CYP3A4 and the UDP-glucuronosyltransferase (UGT) enzymes UGT1A1 and UGT2B7. It shows very minimal metabolism by cytochrome P50 enzymes, with CYP3A4 merely responsible for the greatest degree of metabolism. Since enobosarm is metabolized by CYP3A4, UGT1A1, and UGT2B7, inhibitors and inducers of these enzymes can modify the metabolism and pharmacokinetics of enobosarm. The strong CYP3A4 inhibitor itraconazole was shown to have minimal to no influence on the pharmacokinetics of enobosarm, whereas the strong CYP3A4 inducer rifampin reduced enobosarm peak levels by 23%, elimination half-life by 23%, and area-under-the-curve levels by 43%. The pan-UGT inhibitor probenecid was shown to not affect peak levels of enobosarm but to increase the elimination half-life of enobosarm by 78% and to increase area-under-the-curve levels of enobosarm by 50%. Enobosarm had no effect on the pharmacokinetics of celecoxib (a CYP2C9 substrate) or rosuvastatin (a BCRP substrate). Based on the preceding findings, it was concluded that enobosarm poses low risk for clinically relevant drug interactions.
Through hundreds of photographs, she demonstrates that the image of a female displaying her vulva is not specific to European religious art or architecture, but that similar images are found in the visual arts and in mythical narratives of goddesses and heroines parting their thighs to reveal what she calls, "sacred powers". Her theory is that "the image is so rooted in our psyches that it seems as if the icon is the original cosmological center of the human imagination".
== Further reading == Biochemistry textbook reference, from the NCBI bookshelf – Jeremy M. Berg; John L. Tymoczko; Lubert Stryer (eds.). "18.4. A Proton Gradient Powers the Synthesis of ATP". Biochemistry (5th ed.). W. H. Freeman. Archived from the original on August 3, 2007. A set of experiments aiming to test some tenets of the chemiosmotic theory – Ogawa S, Lee TM (August 1984). "The relation between the internal phosphorylation potential and the proton motive force in mitochondria during ATP synthesis and hydrolysis". The Journal of Biological Chemistry. 259 (16): 10004–10011. doi:10.1016/S0021-9258(18)90918-X. PMID 6469951.
Sources: en.wikipedia.org
IS-159, also known as serotonin-O-carboxymethylglycyltyrosinamide, is a triptan-like serotonin 5-HT1B and 5-HT1D receptor agonist which was under development for the treatment of migraine but was never marketed. It is taken intranasally or subcutaneously. The drug is a small serotonin-containing peptide and is described as being peripherally selective. It acts as a selective and potent serotonin 5-HT1B and 5-HT1D receptor agonist (Ki = 3.2 nM and 1.6 nM, respectively). IS-159 has more than 300-fold lower affinity for the serotonin 5-HT1A receptor (Ki = 1,000) and is inactive at the serotonin 5-HT1E and 5-HT1F receptors (Ki = >10,000 nM). The drug's pharmacokinetics in humans have been studied. IS-159 was originated by Immunotech in France and was under development by Immunotech and The Medicines Company in the 1990s and early 2000s, but development was discontinued in 2003. The drug reached phase 2 clinical trials prior to the discontinuation of its development.
== Prevalence == Over 30% of athletes participating in 2011 World Championships in Athletics admitted having used banned substances during their careers. According to a study commissioned by the World Anti-Doping Agency (WADA), actually 44% of them had used them. Nevertheless, only 0.5% of those tested were caught. The entire Russian track and field team was banned from the 2016 Olympic Games, as the Russian State had sponsored and essentially sanctioned their doping program.
Relative humidity The relative humidity of air is defined as the partial pressure of water vapour divided by the saturated vapour pressure at the same temperature and total pressure. If the temperature is kept constant, lower relative humidities result in higher drying rates due to the increased moisture gradient in wood, resulting from the reduction of the moisture content in the surface layers when the relative humidity of air is reduced. The relative humidity is usually expressed on a percentage basis. For drying, the other essential parameter related to relative humidity is the absolute humidity, which is the mass of water vapour per unit mass of dry air (kg of water per kg of dry air). However, its influenced by the amount of water in the heated air. Air circulation rate Drying time and timber quality depend on the air velocity and its uniform circulation. At a constant temperature and relative humidity, the highest possible drying rate is obtained by rapid circulation of air across the surface of wood, giving rapid removal of moisture evaporating from the wood. However, a higher drying rate is not always desirable, particularly for impermeable hardwoods, because higher drying rates develop greater stresses that may cause the timber to crack or distort. At very low fan speeds, less than 1 m/s, the air flow through the stack is often laminar flow, and the heat transfer between the timber surface and the moving air stream is not particularly effective.
=== Biosynthesis === Chloramphenicol is produced by Streptomyces venezuelae. Its biosynthesis has been partially elucidated. A portion of the structure originates from the shikimate pathway, in which aromatic amino acids are formed. The non-proteinogenic amino acid para-aminophenylalanine is also accessible via this pathway (step 1 in the scheme). This intermediate is bound to a peptidyl carrier protein via a thioester (2) and hydroxylated at the benzyl position (3). The amino group is then oxidized to the nitro group (4), the dichloroacetyl group is introduced from an unknown precursor (5), and the intermediate is released as an aldehyde (6). Reduction of the aldehyde group to the alcohol (7) yields chloramphenicol.
== Pharmacokinetics == As R7 is a slightly larger molecule than tropoflavin, 72.5 mg R7 is molecularly equivalent to 50 mg tropoflavin. Relative to a roughly molecularly equivalent dose of tropoflavin, the area-under-curve levels of R7 were found to be 7.2-fold higher upon oral administration to mice, and R7 hence has a greatly improved oral bioavailability in mice of approximately 35%. Moreover, whereas tropoflavin itself is mostly metabolized in mice within 30 minutes, tropoflavin as a metabolite was still detectable in plasma at 8 hours after administration with R7, indicating that R7 sustainably releases tropoflavin into circulation. In accordance, the terminal half-life of R7 is about 195 minutes (3.25 hours) in mice. The Tmax of R7 is about 60 minutes in mice, and its Cmax for a 78 mg/kg dose was 262 ng/mL, whereas that for a 50 mg/kg dose of tropoflavin was 70 ng/mL.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。